Showing 4521-4530 of 5646 results for "".
- Uplinza Approved in Japan for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD)https://modernod.com/news/uplinza-approved-in-japan-for-the-prevention-of-relapses-of-neuromyelitis-optica-spectrum-disorder-nmosd/2479009/Horizon Therapeutics announced that its strategic partner Mitsubishi Tanabe Pharma Corporation (MTPC) has received manufacturing and marketing approval of Uplinza for the prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica) from the Japanese Ministry o
- Judy F. Gordon, DVM, Founder of ClinReg Consulting Services, Retireshttps://modernod.com/news/judy-f-gordon-dvm-founder-of-clinreg-consulting-services-retires/2479004/Medical device and pharmaceutical consulting company ClinReg Consulting Services announced the retirement of its founder and president, Judy F. Gordon, DVM. Dr. Gordon has worked in the clinical and regulatory industry for more than 35 years, beginning with her career in the pharmaceutical
- VSY Biotechnology Signs Agreement with Wakamoto Pharmaceutical on Intraocular Lens Productshttps://modernod.com/news/vsy-biotechnology-signs-agreement-with-wakamoto-pharmaceutical-on-intraocular-lens-products/2479003/VSY Biotechnology announced an agreement with Wakamoto Pharmaceutical to provide new treatments for cataract surgeries in Japan. The agreement includes a licensing arrangement with Wakamoto Pharmaceutical to develop and launch IOLs in Japan. “We’re very excited to work with Wak
- Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestonehttps://modernod.com/news/nicoxs-ncx-470-mont-blanc-phase-3-glaucoma-trial-reaches-50-enrollment-milestone/2478999/Nicox announced that 50% of patients in the Mont Blanc NCX 470 phase 3 glaucoma clinical trial have now been randomized out of a target of 670, with topline results currently on track to be announced during Q2 2022. “We have been successful in maintaining a good recruitment rate in the Mon
- Santen EMEA Appoints Dr. Ioana Grobeiu as Vice President, Medical Affairshttps://modernod.com/news/santen-emea-appoints-dr-ioana-grobeiu-as-vice-president-medical-affairs/2479000/Santen EMEA has announced the appointment of Dr. Ioana Grobeiu as Vice President, Medical Affairs. With over 20 years of experience in pharmaceuticals, Dr. Grobeiu will lead the medical affairs strategy and report to Luis Iglesias, President and Head of Santen EMEA. Dr. Grobeiu will delive
- AdHawk Microsystems Launches AdHawk MindLink Eye Tracking Researchhttps://modernod.com/news/adhawk-microsystems-launches-adhawk-mindlink-eye-tracking-research/2479002/AdHawk Microsystems announced the launch of AdHawk MindLink wearable eye tracking system. AdHawk MindLink produces accurate eye movement data to provide deep insights into human behavior, ocular, and neurological health. Delivered in the form of lightweight and comfortable glasses, the AdHawk sys
- SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Rochehttps://modernod.com/news/semathera-enters-into-a-research-collaboration-and-exclusive-license-agreement-with-roche/2478997/SemaThera announced the signing of a multi-year research collaboration and licensing agreement with Roche to advance SemaThera’s new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases. Terms of the deal were not disclosed. “We are very
- Nidek Launches RT-6100 CB for Windows to Enhance Refraction Workflowhttps://modernod.com/news/nidek-launches-rt-6100-cb-for-windows-to-enhance-refraction-workflow/2478994/Nidek has announced the launch of RT-6100 CB for Windows, an optional control software for the RT-6100 Intelligent Refractor and the TS-610 Tabletop Refraction System. As the environment is shifting and the dem
- AstraZeneca’s COVID-19 Vaccine Shows 79% Efficacy in Pivotal US Studyhttps://modernod.com/news/astrazenecas-covid-19-vaccine-shows-79-efficacy-in-pivotal-us-study/2478995/AstraZeneca on Monday announced that its vaccine AZD1222 demonstrated efficacy of 79% at preventing symptomatic COVID-19 in a late-stage study conducted in the US. Results also showed that the vaccine had 100% efficacy at preventing severe disease and hospitalization, with comparable effectivenes
- SIFI Receives Marketing Authorization for Ophthalmic Products in in Turkeyhttps://modernod.com/news/sifi-recevies-marketing-authorizations-for-ophthalmic-products-in-in-turkey/2478996/SIFI, has announced that the Turkish Medicines and Medical Devices Agency (TMMDA) has approved the transfer of marketing authorizations from its former local distributor to its wholly owned subsidiary SIFI İlaç A.S. The approvals cover different formulations of ophthalmic drugs Netira, Netildex,